Scarica l'app Stockscreener
5.735
2.05%
0.115
Precedente Chiudi:
$5.62
Aprire:
$5.66
Volume 24 ore:
5,618
Relative Volume:
0.10
Capitalizzazione di mercato:
$55.30M
Reddito:
$1.15M
Utile/perdita netta:
$-46.90M
Rapporto P/E:
-1.1428
EPS:
-5.0182
Flusso di cassa netto:
$-42.37M
1 W Prestazione:
-9.40%
1M Prestazione:
-24.93%
6M Prestazione:
-64.60%
1 anno Prestazione:
-23.53%
Intervallo 1D:
$5.63
$5.83
Intervallo di 1 settimana:
$5.31
$6.80
Portata 52W:
$5.31
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
5.71 | 54.42M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
450.89 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.55 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.90 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.29 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.69 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics (MCRB) Faces Sharp Decline, Tests Key Support LevelsETH Profile - newsline.com
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - Yahoo Finance
Seres Therapeutics (MCRB) Slips 2.62% as Shares Test Key Support at $6.00Bull Pennant - newsline.com
Cambridge biotech surrenders half its lab space amid cash crunch - The Business Journals
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics (MCRB) Secures Cash Runway Extension Through Key Transactions - GuruFocus
Seres Therapeutics Secures $25M from Nestlé, Restructures Lease to Extend Cash Runway Into 2027 - Minichart
Seres Therapeutics secures $25M from Nestlé Health Science By Investing.com - Investing.com South Africa
Seres Therapeutics Reshapes Finances with Lease Restructuring - TipRanks
Seres Therapeutics Extends Cash Runway to 2027 Through Financial Restructuring and Lease Adjustments - geneonline.com
Seres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial Position - Quiver Quantitative
Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027 - TradingView
Seres Therapeutics secures $25M from Nestlé Health Science - Investing.com
Seres Therapeutics (Nasdaq: MCRB) extends cash runway into 2027 - Stock Titan
Drugmaker Seres gets $25M from Nestlé, cuts Boston-area lab lease costs - Stock Titan
Seres Therapeutics, Inc. Files 8-K Current Report with SEC Detailing Corporate Information (May 30, 2026) - Minichart
[8-K] Seres Therapeutics, Inc. Reports Material Event - Stock Titan
Seres Therapeutics (MCRB) Slips 3.4%, Testing Key Support at $6.95Range Breakout - newsline.com
Seres Therapeutics (MCRB) Declines 2.18% as Stock Approaches Key SupportHigh Reward Trades - newsline.com
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Seres Therapeutics (MCRB) Edges Higher Amid Steady Support and Resistance DynamicsDark Pool Volume - The Legal Advocate
Seres Therapeutics (MCRB) Declines 5.93% as Selling Pressure IntensifiesLow Risk Entry Stocks - The Legal Advocate
MCRB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues R&D FocusEarnings Beat Streak - The Legal Advocate
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Seres Therapeutics (MCRB) Q1 2026 Miss: What Went WrongEPS Surprise History - Newser
Seres Therapeutics (MCRB) Q1 2026 Miss: Should Investors Be Worried?EPS Estimate Trend - The Legal Advocate
MCRB: AI-driven microbiome therapeutics pipeline advances toward key clinical and commercial milestones - TradingView
Teresa L. Young sells shares; MCRB (NASDAQ: MCRB) files Form 144 notice - Stock Titan
Officer at Seres Therapeutics (NASDAQ: MCRB) sells 79 shares under 10b5-1 tax plan - Stock Titan
Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan - Stock Titan
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Seres Therapeutics stock (US81750R1023): Q1 2026 results and private placement - AD HOC NEWS
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - The Manila Times
How to watch Seres Therapeutics’ BioConnect investor presentation - Stock Titan
How Seres Therapeutics (MCRB) balances short term and long term focus | Q1 2026: EPS Misses ViewsNCAV - Newser
MSN Money - MSN
The working capital efficiency at Seres Therapeutics (MCRB) | Q1 2026: EPS Misses EstimatesProfit Margin - newser.com
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics 1Q 2026: Revenue $358K, EPS $(2.08) — 10-Q Summary - TradingView
Seres Therapeutics (NASDAQ: MCRB) Q1 2026 loss and going-concern risk - Stock Titan
Seres Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) Q1 2026 results and cash runway - Stock Titan
Seres awaits SER-155 data in weeks with cash through Q3 - Stock Titan
Seres presents preclinical data on IBD drug candidate SER-603 - Investing.com UK
Seres presents preclinical data on IBD drug candidate SER-603 By Investing.com - Investing.com South Africa
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - The Manila Times
Experimental IBD microbiome therapy earns DDW poster honor - Stock Titan
Seres Therapeutics Presents Preclinical Data at Digestive - GlobeNewswire
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):